Phase 4 clinical trial：Priority of COVID-19 vaccination in Japan

On December 18, 2020, Pfizer (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) applied to the Japanese Ministry of Health, Labor and Welfare for manufacturing and marketing approval of the COVID-19 vaccine (BNT162b2). The Japanese government is doing the preparations for the vaccination of COVID-19 vaccine (BNT162b2) to the Japanese people.

From late February 2021, the COVID-19 vaccine developed by Pfizer (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) will be given in advance to medical workers (about 10,000 people) working at the National Hospital Organization medical institution. Therefore, post-approval verification of the COVID-19 vaccine (Phase 4 clinical trial) will be conducted.

From mid-March 2021, the COVID-19 vaccine will be given priority to healthcare workers (about 3 million people).

From the end of March 2021, the COVID-19 vaccine will be given priority to elderly people aged 65 and over (about 30 to 40 million people).

General COVID-19 vaccination may begin around May 2021.

The Japanese government must pay close attention to the results of the Phase 4 clinical trial. Depending on the results of the Phase 4 clinical trial, The Japanese government should immediately consider vaccination with COVID-19 vaccines from other companies such as AstraZeneca plc.

A low temperature freezer at -70 ° C cannot be used with a normal outlet. The person in charge must consider the problem of electrical wiring work and the total power of the building. The person in charge must be familiar with this point.

New Engl J Med. Published on January 2021. by Kyoto@Takuma H